CytomX Therapeutics (NASDAQ:CTMX) specializes in creating innovative cancer treatments through its proprietary technology, Probody® Therapeutics. This unique approach focuses on developing treatments that are more selective in targeting cancer cells, potentially reducing side effects associated with traditional cancer therapies. Their portfolio includes exciting projects in various stages of development, aimed at treating a wide range of cancers. CytomX's objective is to harness the power of its platform to advance oncology medicine and improve the outcomes for patients facing this challenging disease. By targeting the unmet needs in cancer treatment, CytomX strives to bring pioneering therapies from the lab to the clinic.